Real-world outcomes of combined therapy of photodynamic therapy with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5454
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Real-world outcomes of combined therapy of photodynamic therapy with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy ; volume:36 ; number:10 ; day:28 ; month:9 ; year:2021 ; pages:1934-1939 ; date:10.2022
Eye ; 36, Heft 10 (28.9.2021), 1934-1939, 10.2022
- Creator
-
Liu, Siyin
Chhabra, Ramandeep
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41433-021-01773-x
- URN
-
urn:nbn:de:101:1-2022120921244532035188
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Liu, Siyin
- Chhabra, Ramandeep
- SpringerLink (Online service)
Other Objects (12)
Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: A meta-analysis
Anti-Vascular Endothelial Growth Factor Therapy Regimens for Polypoidal Choroidal Vasculopathy: A Systematic Review
One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy
Seven-year outcomes of combined treatment of anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy; according to polypoidal lesion regression
One-Year Outcome of Aflibercept and Photodynamic Therapy in a Caucasian Patient with Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab and Photodynamic Therapy
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization
Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy
Correction to “Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization”
Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy
Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: A meta-analysis
Anti-Vascular Endothelial Growth Factor Therapy Regimens for Polypoidal Choroidal Vasculopathy: A Systematic Review
One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy
Seven-year outcomes of combined treatment of anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy; according to polypoidal lesion regression
One-Year Outcome of Aflibercept and Photodynamic Therapy in a Caucasian Patient with Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab and Photodynamic Therapy
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization
Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy
Correction to “Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization”
Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy
Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: A meta-analysis
Anti-Vascular Endothelial Growth Factor Therapy Regimens for Polypoidal Choroidal Vasculopathy: A Systematic Review
One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy
Evaluating photodynamic therapy versus brolucizumab as a second-line treatment for polypoidal choroidal vasculopathy
Seven-year outcomes of combined treatment of anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy; according to polypoidal lesion regression
One-Year Outcome of Aflibercept and Photodynamic Therapy in a Caucasian Patient with Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab and Photodynamic Therapy
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization
Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy
Correction to “Light‐Activated Anti‐Vascular Combination Therapy against Choroidal Neovascularization”
Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy